Articles related to ANTITHROMBOTIC THERAPY

In an observational target trial emulation of patients with atrial fibrillation and mitral stenosis, DOACs were associated with higher 1-year stroke risk than warfarin. Bleeding and all-cause mortality risks did not differ between groups.

A new ACC scientific statement summarizes current evidence for antiplatelet therapy across primary prevention, ACS, PCI, CAD, and PAD management. The document emphasizes individualized assessment of ischemic and bleeding risks.

Pediatric pharmacists recorded 1,130 antithrombotic-related interventions involving 26.4% of 2,264 critically ill children across 9 U.S. children’s hospitals during 697 shifts from July 2023 to November 2024, with 74.7% of those interventions occurring in the pediatric cardiac ICU and 90.4% of initiation and management interventions involving anticoagulant agents.

The FDA accepted asundexian’s secondary-stroke-prevention application for Priority Review, supported by phase 3 OCEANIC-STROKE results in noncardioembolic ischemic stroke.

First-line pulsed field catheter ablation outperformed antiarrhythmic drug therapy for rhythm control at one year in patients with persistent atrial fibrillation, with similar serious adverse event rates.

“The idea of preserving and reducing thrombosis without increasing bleeding is very, very exciting.” — Roxana Mehran, MD, SCAI 2025